Newron Pharmaceuticals S.p.A. (LON:0QOI)
London
· Delayed Price · Currency is GBP · Price in CHF 7.03
+0.53 (8.15%)
At close: Apr 23, 2025
Newron Pharmaceuticals Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 51.39 | 6.79 | 5.95 | 5.76 | 5.26 | Upgrade
|
| Other Revenue | - | 2.26 | 0.14 | - | - | Upgrade
|
| Revenue | 51.39 | 9.06 | 6.09 | 5.76 | 5.26 | Upgrade
|
| Revenue Growth (YoY) | 467.41% | 48.62% | 5.76% | 9.59% | -25.29% | Upgrade
|
| Gross Profit | 51.39 | 9.06 | 6.09 | 5.76 | 5.26 | Upgrade
|
| Selling, General & Admin | 11.58 | 7.53 | 7.39 | 7.39 | 8.47 | Upgrade
|
| Research & Development | 13.64 | 13.15 | 12.01 | 10.73 | 14.85 | Upgrade
|
| Operating Expenses | 25.22 | 20.69 | 19.4 | 18.12 | 23.32 | Upgrade
|
| Operating Income | 26.17 | -11.63 | -13.3 | -12.36 | -18.07 | Upgrade
|
| Interest Expense | -4.35 | -4.17 | -3.95 | -2.92 | -2.24 | Upgrade
|
| Interest & Investment Income | 0.14 | 0.18 | 0.06 | 0.05 | 0.06 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.1 | -0.07 | 0.12 | 0.2 | -0.17 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.47 | -0.51 | -0.4 | 0.13 | 0.79 | Upgrade
|
| EBT Excluding Unusual Items | 21.39 | -16.2 | -17.47 | -14.88 | -19.62 | Upgrade
|
| Pretax Income | 21.39 | -16.2 | -17.47 | -14.88 | -19.62 | Upgrade
|
| Income Tax Expense | 5.55 | 0.02 | 0.02 | 0.02 | 1.38 | Upgrade
|
| Net Income | 15.84 | -16.22 | -17.49 | -14.9 | -21 | Upgrade
|
| Net Income to Common | 15.84 | -16.22 | -17.49 | -14.9 | -21 | Upgrade
|
| Shares Outstanding (Basic) | 19 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Outstanding (Diluted) | 21 | 18 | 18 | 18 | 18 | Upgrade
|
| Shares Change (YoY) | 15.30% | - | - | - | - | Upgrade
|
| EPS (Basic) | 0.85 | -0.91 | -0.98 | -0.84 | -1.18 | Upgrade
|
| EPS (Diluted) | 0.77 | -0.91 | -0.98 | -0.84 | -1.18 | Upgrade
|
| Free Cash Flow | -17.63 | -10.15 | -11.11 | -11.47 | -15.62 | Upgrade
|
| Free Cash Flow Per Share | -0.86 | -0.57 | -0.62 | -0.64 | -0.88 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | Upgrade
|
| Operating Margin | 50.93% | -128.40% | -218.28% | -214.46% | -343.59% | Upgrade
|
| Profit Margin | 30.83% | -179.13% | -287.05% | -258.61% | -399.35% | Upgrade
|
| Free Cash Flow Margin | -34.30% | -112.08% | -182.31% | -198.98% | -297.11% | Upgrade
|
| EBITDA | 26.2 | -11.49 | -13.27 | -12.31 | -17.99 | Upgrade
|
| EBITDA Margin | 50.98% | -126.89% | -217.67% | -213.64% | - | Upgrade
|
| D&A For EBITDA | 0.02 | 0.14 | 0.04 | 0.05 | 0.07 | Upgrade
|
| EBIT | 26.17 | -11.63 | -13.3 | -12.36 | -18.07 | Upgrade
|
| EBIT Margin | 50.93% | -128.40% | -218.28% | -214.46% | - | Upgrade
|
| Effective Tax Rate | 25.95% | - | - | - | - | Upgrade
|
| Revenue as Reported | 51.39 | 9.06 | 6.09 | 5.76 | 5.26 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.